Company Overview - Cartesian Therapeutics is a clinical-stage biotechnology company focused on pioneering mRNA cell therapies for autoimmune diseases [2] - The lead asset, Descartes-08, is in Phase 2b clinical development for generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with plans for a Phase 2 basket trial in additional autoimmune indications [2] - The clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T [2] Upcoming Events - The company management is scheduled to participate in several investor conferences in February and March 2025, including: - A fireside chat at the H.C. Wainright & Co. 3rd Annual Cell Therapy Virtual Conference on February 25, 2025 [3] - A presentation at the TD Cowen 45th Annual Health Care Conference on March 3, 2025, in Boston, MA [3] - A fireside chat at the Leerink Global Healthcare Conference on March 10, 2025, in Miami, FL [3] - Live webcasts of these presentations will be accessible on the company's website, with archived replays available for a limited time [1]
Cartesian Therapeutics to Participate in Upcoming Investor Conferences